• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Hypercalcemia - Pipeline Review, H2 2011 - Product Image

Hypercalcemia - Pipeline Review, H2 2011

  • ID: 1964219
  • November 2011
  • 25 pages
  • Global Markets Direct

Hypercalcemia - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Hypercalcemia - Pipeline Review, H2 2011', provides an overview of the Hypercalcemia therapeutic pipeline. This report provides information on the therapeutic development for Hypercalcemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypercalcemia. 'Hypercalcemia - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hypercalcemia.
- A review of the Hypercalcemia products under development by companies and universities/research institutes based on information derived READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hypercalcemia Overview
Therapeutics Development
An Overview of Pipeline Products for Hypercalcemia
Hypercalcemia Therapeutics under Development by Companies
Hypercalcemia Therapeutics under Investigation by Universities/Institutes
Early Clinical Stage Products
Comparative Analysis
Hypercalcemia Therapeutics - Products under Development by Companies
Hypercalcemia Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Hypercalcemia Therapeutics Development
Genta Incorporated
Hypercalcemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
G4544 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cholecalciferol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hypercalcemia - Featured News
Dec 23, 2004: NPS Completes $175 Million Note Offering Backed By Sensipar Royalties
Jul 30, 2004: Mimpara -- Cinacalcet HCl -- Receives Positive Regulatory Opinion For Approval In Europe
Apr 08, 2004: Sensipar Pivotal Studies In Over 700 Patients Published In New England Journal Of Medicine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Hypercalcemia, H2 2011
Products under Development for Hypercalcemia – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Genta Incorporated, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011

List of Figures
Number of Products under Development for Hypercalcemia, H2 2011
Products under Development for Hypercalcemia – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Early Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos